ABA Therapy M&A: Autism Services Valuation, Staffing, and Diligence

ABA value is created between authorization and collection

ABA businesses are often described through growth in referrals, diagnoses, clients, centers, and approved treatment hours. Those measures can indicate demand, but they do not establish transaction value by themselves. A buyer must determine how much of that demand can be staffed, delivered, documented, billed, collected, and sustained after closing. The economic value of one authorized hour depends on whether a qualified clinician is available, whether the session occurs, whether the record supports the service, whether the claim is accepted, and how long the payer takes to remit cash.

This operating sequence makes ABA unusually sensitive to small breakdowns that compound across a large service base. A center can appear full while delivering materially fewer hours than authorized. A growing client roster can conceal cases waiting for RBT assignments. A strong income statement can include claims that are slow, denied, or vulnerable to recoupment. A high reported EBITDA margin can reflect underinvestment in recruiting, supervision, compliance, or revenue-cycle infrastructure that a buyer will need to add after closing.

Owners should therefore evaluate the company through the buyer’s evidence chain before buyers define it for them. A qualified transaction adviser should understand how payer, clinical, staffing, center-level, and financial data combine into accepted EBITDA, valuation, structure, and closing certainty.

Executive summary

ABA and autism-services businesses continue to attract strategic acquirers, private equity sponsors, and sponsor-backed behavioral health platforms because demand is durable, ownership remains fragmented, and scaled infrastructure can improve recruiting, supervision, payer administration, revenue cycle, compliance, reporting, and expansion. The strongest targets do more than show growth. They demonstrate that referrals convert into appropriate starts of care, authorizations remain current, clinicians can be recruited and retained, delivered hours are documented, claims collect, and center or home-based economics remain stable across markets.

Buyers underwrite the referral-to-cash chain by separating active census from economic census and authorized hours from scheduled, delivered, documented, billed, allowed, and collected hours. They examine BCBA capacity, RBT turnover, supervision, credentialing, payer mix, rate adequacy, denials, state exposure, center maturity, cancellation behavior, geographic density, and clinical-director dependence. Those variables determine whether the reported EBITDA base can survive quality-of-earnings review and whether forecast growth can be delivered without disproportionate recruiting, working capital, compliance, or facility investment.

Valuation is therefore the result of operating evidence rather than a standalone multiple. The broader Behavioral Health Company Valuation framework explains how buyers determine enterprise value, while Behavioral Health Valuation Multiples explains why scale, payer quality, workforce, and risk affect the range. In ABA, the most important question is how much buyer-accepted EBITDA and free cash flow remain after adjusting for authorization leakage, clinician capacity, recruiting, supervision, denials, compliance, center ramp, management, and post-close investment.

Owners should compare proposals across accepted EBITDA, enterprise value, cash at close, rollover, earnouts, escrows, working capital, financing, approvals, employment, transition, integration, and probability of closing. A sponsor-backed platform may offer compelling strategic fit but require more retained equity and post-close leadership. A strategic buyer may offer more immediate integration and cash but place a different value on local density, payer contracts, clinicians, or center capacity. The full acquirer comparison appears in Behavioral Health Acquirers.

Key takeaways

• Referral volume, waitlists, active clients, and authorized hours are demand indicators—not substitutes for staffed, documented, collectible revenue.
• Buyers separate authorized, scheduled, delivered, documented, billed, allowed, and collected hours to identify leakage and forecast risk.
• BCBA capacity and supervisory leverage can constrain RBT productivity, client starts, center growth, and revenue more than headline demand.
• RBT recruiting and turnover should be measured by productive capacity, time to full schedule, tenure, cancellation exposure, compensation, and local labor supply.
• Center-based, in-home, school-based, and hybrid models have different fixed costs, travel burdens, cancellation patterns, supervision needs, and scaling economics.
• Payer rates support value only when they cover the labor, supervision, documentation, administration, and denial burden required to deliver compliant care.
• Location-level cohorts and mature-center economics are more informative than consolidated averages when buyers evaluate de novo growth and platform scalability.
• Documentation, rendering-provider support, credentialing, and claim-to-record reconciliation can affect EBITDA, escrows, indemnities, and whether a buyer closes.
• Qualified buyer competition improves the seller’s ability to compare price, cash at close, rollover, contingent value, integration, and certainty.

Why ABA and autism services continue to attract buyers

ABA remains attractive because demand is durable, ownership is fragmented, and providers can create value by improving access, recruiting, supervision, payer administration, revenue cycle, compliance, technology, and local density. A strategic acquirer may value a center footprint, payer relationships, clinicians, referrals, school relationships, or state access. A sponsor-backed platform may value the same company as an add-on that strengthens density, fills excess infrastructure, adds a new payer or program, or accelerates expansion.

The investment thesis does not eliminate operating constraints. A provider may have substantial unmet demand and still struggle to recruit BCBAs, develop supervisors, retain RBTs, secure authorizations, or collect claims. Buyers therefore distinguish sector attractiveness from company quality. A business earns premium consideration when it demonstrates a repeatable operating system rather than a collection of favorable demographic and market statistics.

Buyer interest should be translated into company-specific competition. One platform may place more value on a target’s state footprint, another on mature centers, another on commercial payer relationships, and another on a strong BCBA leadership bench. Disciplined confidential buyer outreach can identify which strategic and financial acquirers have the most defensible fit rather than assuming every buyer applies the same thesis.

The strategic rationale must be distinguishable from a broad category thesis. How Strategic Buyers Value Companies explains why an acquirer may pay for density, capacity, relationships, or integration benefits that are not available to every bidder. ABA sellers should identify those buyer-specific benefits without presenting unsupported synergy as guaranteed value.

Private equity activity does not automatically create a premium

Private equity interest can widen the buyer universe, but a sponsor still prices the target through accepted EBITDA, debt capacity, integration costs, growth investment, and expected exit returns. The buyer may like ABA and still reduce value when the company has unsupported add-backs, high payer concentration, weak documentation, unstable staffing, immature centers, or a growth plan that requires more capital than management recognizes.

Buyers negotiate earnings and multiple together. A seller may focus on a high observed multiple while the buyer applies it to lower normalized EBITDA after adjusting for recruiting, supervision, revenue-cycle resources, clinical leadership, compliance, or uncollectible claims. Do Buyers Use EBITDA Multiples? explains why the multiple is an output of underwriting. Business Valuation Methods explains how market, income, transaction, and buyer-return approaches frame value.

The broad sponsor thesis—including leverage, governance, rollover, management incentives, and exit assumptions—is addressed in Private Equity in Behavioral Health. This article focuses on the ABA operating evidence that determines whether that thesis is financeable.

A sponsor also tests entry price against the return model rather than applying a category premium mechanically. How Private Equity Actually Prices Deals in Practice explains how accepted EBITDA, leverage, investment needs, growth, and exit assumptions interact. The seller should understand which operating assumptions allow the buyer to support the indication and which unresolved risks may later become a retrade.

Strategic buyers, sponsors, and sponsor-backed platforms underwrite different paths to value

A strategic provider may value local density, payer access, clinician capacity, school relationships, a referral base, or a center footprint that improves its existing operations. It may have infrastructure that reduces incremental overhead and allows it to integrate the target quickly. That synergy can support a strong valuation, but the buyer may also expect rapid system conversion, compensation changes, leadership consolidation, or brand integration.

A standalone private equity sponsor needs a complete platform case. It must underwrite management, systems, compliance, lender reporting, organic growth, de novos, acquisitions, and a future exit. An existing sponsor-backed platform can evaluate the target as a strategic add-on and may accept infrastructure gaps because finance, revenue cycle, recruiting, clinical governance, and compliance already exist at the platform.

The company should be positioned according to its actual role. The full buyer landscape appears in Behavioral Health Acquirers, while Pharma Services Acquirers provides a useful cross-healthcare comparison showing how strategic and financial buyers apply different evidence in regulated services transactions.

Buyer-specific benefits should be tested rather than assumed. How Synergies Affect Acquisition Valuations explains why cost and revenue benefits support value only when the acquirer can execute them. In ABA, the most credible synergies often involve density, recruiting, supervisor coverage, revenue cycle, payer administration, and shared management—not automatic reductions in clinical labor.

Platform, add-on, and tuck-in logic in ABA therapy M&A

An ABA platform must support independent management, institutional reporting, clinical leadership, recruiting, payer administration, revenue cycle, compliance, de novo growth, acquisitions, integration, and lender requirements. Revenue and EBITDA scale help, but the platform label ultimately depends on whether the company can operate as the organizational base for a larger enterprise.

An add-on can be smaller, more concentrated, or less institutional when the existing platform can supply the missing infrastructure. A target may still command strong interest if it adds a priority state, mature centers, scarce BCBAs, commercial contracts, a school-based program, or local density. A tuck-in may be valued primarily for a location, team, payer relationship, or census that can be absorbed into the buyer’s operating model.

For acquisitive platforms, Buy-Side M&A Advisory can connect acquisition thesis, target screening, valuation, diligence, financing, negotiation, and integration. How Buyers Evaluate Acquisition Targets explains why strategic role can matter as much as standalone size.

The Buy-Side M&A Process should carry the platform thesis through sourcing, indications, diligence, financing, documentation, and post-close accountability. A target that appears attractive in isolation can weaken the platform if integration resources, payer enrollment, or clinical leadership are already stretched.

What makes an ABA provider scalable and transferable?

Scalable providers can reproduce the referral-to-cash process without depending on one founder, one clinical director, one payer contact, or one center manager. They have documented intake, assessment, authorization, staffing, scheduling, supervision, documentation, billing, collections, and quality procedures. Their leaders can explain performance by state, payer, location, client cohort, clinician type, and time period.

Transferability also requires workforce and relationship continuity. Buyers evaluate whether BCBAs, RBTs, center leaders, families, referral sources, schools, and payers are likely to remain after ownership changes. Employment agreements and retention programs help, but the deeper issue is whether trust and operating knowledge belong to the organization or reside primarily with a small number of people.

A highly profitable founder-led company may be a premium add-on without being a platform. Why Founder-Led Businesses Are Not Ready for Sale explains how dependency affects transferability. The seller should address those risks before buyers convert them into lower accepted EBITDA, longer transition, rollover, or contingent value.

A structured Sell-Side Readiness Assessment can identify where the company’s evidence, leadership, and controls fall short of the buyer’s platform expectations. The purpose is not to imitate a public company; it is to make the operating model understandable, transferable, and supportable under diligence.

The ABA referral-to-cash underwriting framework

The referral-to-cash chain is the central operating model for ABA diligence. Each stage creates a distinct conversion rate, timing issue, and risk. A buyer needs to know not only how many referrals enter the system, but how many qualify, complete intake and assessment, receive authorization, obtain staff, start care, remain active, receive the planned services, generate compliant records, produce clean claims, and convert into cash.

The stages must reconcile. The number of clients, hours, claims, and dollars should make sense across clinical, scheduling, billing, and financial systems. When management cannot explain the variance between authorized and collected revenue, the buyer adopts a more conservative interpretation across the entire forecast.

The chain also explains why buyers ultimately value cash rather than operating activity alone. Why Buyers Focus on Cash Flow, Not Profit describes the broader principle. In ABA, the timing and reliability of authorization, delivery, claims, and collections can cause a substantial gap between reported growth and cash available for debt service or reinvestment.

Active census and economic census are not the same

An active client count can overstate economic value when some clients lack current authorization, are temporarily inactive, receive limited hours, wait for staffing, cancel frequently, or generate weak contribution margins. Buyers therefore segment census by payer, location, service setting, start date, authorization status, assigned clinicians, delivered hours, and recent activity.

Economic census is the population producing recurring, supportable, collectible revenue under the current staffing and payer model. It excludes or separately classifies clients who are authorized but unstaffed, assigned but inactive, recently referred, pending renewal, or approaching discharge. That distinction makes forecasts more realistic and allows the buyer to test retention and capacity rather than relying on a single headline number.

Cohort analysis is particularly useful. Buyers compare mature clients with recent starts, evaluate hours delivered over time, and identify whether revenue growth reflects more active clients, more delivered hours, rate changes, acquisitions, or temporary mix. A company that can explain those movements earns more confidence than one that reports census without the underlying economics.

That distinction is one reason EBITDA matters more than revenue in M&A. A larger census does not support value if it requires disproportionate recruiting, supervision, facility, and revenue-cycle expense or if authorized demand cannot be converted into collectible services.

Referral conversion and waitlist quality

A waitlist demonstrates potential demand, but buyers do not value it like contracted backlog. Each entry should be tested for recency, diagnosis, payer eligibility, geography, requested setting, age, schedule, family engagement, authorization status, and staffability. A long list accumulated over several years may include families who found another provider, moved, changed coverage, or no longer seek the same service.

The buyer also asks why the waitlist exists. It may reflect strong market demand and referral relationships, but it may also reveal persistent recruiting constraints, slow intake, assessment bottlenecks, limited center capacity, or payer delays. A provider that has not converted the pipeline under current conditions must explain what will change after closing.

The strongest evidence tracks conversion by referral source, payer, center, and time period. Management should know the percentage of referrals contacted, assessed, authorized, staffed, started, and retained, along with the median time between stages. That operating history is more valuable than an unqualified count.

Authorized, scheduled, delivered, documented, billed, and collected hours

These hour measures answer different questions. Authorized hours describe the payer-approved ceiling. Scheduled hours show the planned service. Delivered hours reflect what occurred. Documented hours show what the clinical record supports. Billed hours reflect what the provider submitted. Allowed hours reflect what the payer accepted. Collected hours reflect actual cash. A company can perform strongly at one stage and leak materially at another.

Buyers calculate conversion ratios by payer, center, client, clinician, and month. Authorized-to-scheduled variance may indicate staffing shortages. Scheduled-to-delivered variance may indicate cancellations, attendance, or travel problems. Delivered-to-documented variance creates compliance and billing risk. Billed-to-allowed variance reveals coding, credentialing, authorization, or payer issues. Allowed-to-collected variance affects AR and cash conversion.

Trend and cohort analysis matter. A strong recent month may not represent a mature operating pattern. Buyers want enough history to separate seasonality, school calendars, holidays, clinician turnover, payer changes, center ramp, and one-time cleanup. The company should be able to explain why each conversion rate changed and what management did in response.

The hour waterfall should reconcile with the earnings bridge used in diligence. Normalized EBITDA and QoE in Middle-Market Valuation explains why operational support is necessary before an adjustment or forecast becomes part of buyer-accepted EBITDA.

Authorization renewal and continuity risk

Authorizations create forward visibility only when the approval is current, the treatment plan remains supported, clinicians are available, and renewal processes are controlled. Buyers review expiration dates, requested and approved hours, partial approvals, denial reasons, appeals, renewal lead time, and the amount of revenue approaching authorization deadlines.

A concentration of renewals immediately after closing can create risk even when historical collections are strong. The buyer may require a closing condition, a specific representation, additional diligence, or a forecast haircut if a material portion of revenue depends on approvals that are pending or supported by inconsistent records.

Management should maintain a forward authorization calendar and quantify revenue by expiration band. The analysis should distinguish ordinary renewals from cases with changing clinical needs, payer scrutiny, or incomplete documentation. Clear visibility allows the seller to frame timing risk rather than let the buyer treat every renewal as uncertain.

Authorization concentration can also affect transaction timing. A buyer may be unwilling to close before a material renewal cohort is resolved, especially if exclusivity removes the seller’s alternatives. Why Buyers Walk Away Late in M&A Deals explains how unresolved assumptions can become closing risk even after significant diligence has occurred.

Payer mix, rate adequacy, and contract economics

Payer mix affects more than the revenue multiple. Buyers analyze rates, authorization behavior, claim edits, denials, appeals, credentialing, payment timing, recoupments, contract assignment, change-of-control provisions, and state concentration. A commercial payer may offer strong rates but difficult authorizations or enrollment. A Medicaid program may provide substantial demand but expose the provider to state-specific rates, rules, and audit practices.

Rate adequacy must be tested against the actual delivery model. The allowed amount needs to support RBT wages, BCBA supervision, non-billable clinical time, recruiting, training, cancellations, travel, center occupancy, billing, compliance, technology, and management. A payer can represent large revenue while producing weak contribution margin after those costs are allocated.

Buyers compare rate history with wage inflation and staffing availability. If compensation has increased faster than reimbursement, the forecast may depend on future rate increases, productivity improvements, or service-mix changes that have not been secured. Payer strength is therefore measured by sustainable cash contribution rather than nominal rate alone.

Concentration and rate pressure influence how buyers discount value. Why Buyers Discount Valuation in Sell-Side M&A explains the broader pattern: risk that cannot be quantified or mitigated is often reflected through a lower earnings base, lower multiple, or contingent structure.

Denials, appeals, recoupments, and overpayment exposure

Current collection percentages do not capture all historical exposure. Buyers review denials by reason, payer, clinician, center, and service type; appeal success and timing; credit balances; refunds; recoupments; payer audits; self-disclosures; and unresolved overpayments. They also compare billing records with clinical documentation to determine whether apparent cash flow could be subject to later takeback.

Recurring denial categories can reveal operational weaknesses. Authorization mismatches may indicate poor renewal controls. Rendering-provider denials may reflect enrollment or credentialing gaps. Unit and time issues can indicate scheduling or documentation problems. Late filing may point to workflow breakdowns rather than isolated error.

The transaction impact can extend beyond EBITDA. Buyers may exclude aged receivables, reduce working capital, require a special escrow, negotiate a specific indemnity, or retain a claim against the seller for identified exposure. Early analysis is more valuable than a broad assurance that denials are “normal for the industry.”

The seller should distinguish a revenue-cycle issue from a compliance exposure. The first may require staffing, workflow, or technology improvement; the second may involve repayment, disclosure, or indemnification. Purchase Price Adjustment in M&A shows how identified balance-sheet and closing exposures can affect value even after enterprise value is negotiated.

BCBA capacity, caseloads, and supervisory leverage

BCBAs perform more than billable clinical work. They assess clients, develop and update treatment plans, supervise RBTs, train caregivers and staff, manage clinical quality, support authorizations, address escalations, and often contribute to recruiting and center leadership. A buyer needs to understand how that time is allocated and whether current caseloads are sustainable.

Headline BCBA count can obscure concentration. One clinical director may supervise a disproportionate share of staff, hold key payer relationships, review most treatment plans, and solve complex cases. Revenue may also be concentrated among a few high-producing BCBAs. The buyer will test tenure, caseload, location coverage, licensure, credentialing, non-billable time, supervision load, management responsibilities, and replacement difficulty.

BCBA capacity can be the binding constraint on RBT growth. Hiring more technicians does not create revenue when supervision, assessment, and clinical leadership cannot support them. The forecast should connect new-client starts and RBT productivity to a realistic BCBA hiring and development plan rather than assuming one clinician can absorb unlimited growth.

Buyers may also compare workforce concentration with other labor-intensive healthcare models. Healthcare Staffing Business Valuation is not an ABA valuation guide, but it illustrates the broader importance of fill rates, clinician supply, retention, client or payer concentration, and cash conversion when labor capacity determines revenue.

RBT recruiting, onboarding, productivity, and turnover

RBT headcount is less important than productive capacity. Buyers track applications, interviews, offers, acceptance, training completion, credentialing, payer enrollment, time to first case, time to full schedule, monthly delivered hours, cancellation exposure, tenure, turnover, and exit reasons. A company may report rapid hiring while losing technicians before they become fully productive.

Compensation should be evaluated across hourly rates, guaranteed hours, cancellations, training, travel, benefits, bonuses, overtime, and progression. A low nominal wage may create expensive turnover and poor schedule stability. A higher wage may support retention but compress margins if payer rates and supervision economics do not support it.

Workforce data should be segmented by center, market, manager, and cohort. Turnover among new hires may indicate onboarding or job-expectation issues; turnover among experienced technicians may reveal compensation, schedule, supervision, culture, or leadership problems. Buyers want to know whether management has identified the cause and whether the remediation is producing measurable improvement.

Staffing improvement should be demonstrated through cohorts rather than anecdotes. Management can compare recruiting source, training completion, time to first case, time to full schedule, ninety-day retention, and delivered hours. That evidence allows a buyer to decide whether recent improvement is durable enough to support forecast revenue.

Clinical-director and founder dependence

Founder dependence in ABA may be clinical, operational, commercial, or relational. The founder may approve treatment plans, supervise key BCBAs, manage payers, oversee recruiting, resolve family concerns, control referrals, or maintain the only complete understanding of performance. A clinical director may carry similar concentration even when the founder is not involved in daily care.

Buyers assess whether responsibilities are documented and distributed. Succession is stronger when regional clinical leaders, center directors, revenue-cycle managers, compliance staff, and finance leaders have clear authority and measurable accountability. A title is not enough if every material decision still returns to one person.

Dependency can affect price, structure, and employment. The buyer may require a longer transition, retention, rollover, earnout, or replacement budget. Sellers should distinguish ownership value from the compensation and obligations required for continued clinical or executive work after closing.

A weak succession plan can make an otherwise attractive company difficult to finance. Why Some Companies Never Sell explains how transferability problems can prevent a business from reaching an executable outcome even when market demand exists.

Credentialing, enrollment, licensure, and provider transferability

Credentialing and enrollment determine whether clinicians can render and bill services under the applicable payer and entity structure. Buyers review provider rosters, effective dates, revalidation, location enrollment, state licensure, exclusions, background checks, and whether claims align with the rendering and billing provider records.

Change of ownership can affect contracts, enrollments, identifiers, and billing continuity. The transaction structure may require new applications, notices, assignments, or interim operating arrangements. A buyer needs a state- and payer-specific plan before signing if a disruption could delay claims or services.

Data-room rosters should reconcile human resources, clinical systems, payer files, claims, and certification records. Inconsistent names, dates, locations, or statuses can suggest that management lacks control over the provider base. Organized records support both compliance and integration planning.

The transaction form can change how contracts and enrollments transfer. Asset and equity transactions can produce different consequences for contracts, identifiers, liabilities, payer notices, and operational continuity, so ABA-specific consequences must be evaluated with qualified healthcare counsel and payer specialists.

Compensation normalization and workforce investment

Buyer-accepted EBITDA should include the recurring cost of operating a stable clinical workforce. Sellers may identify one-time recruiting campaigns, signing bonuses, or overtime spikes as adjustments. Buyers test whether those costs reflect a temporary event or the ongoing reality of the local labor market.

Underinvestment can inflate reported margins. A company may need additional recruiters, trainers, clinical leaders, schedulers, compliance staff, or retention programs to sustain growth. The buyer will normalize those costs even when they do not appear in historical results. Conversely, a temporary staffing problem may support an adjustment when the company can show that a specific disruption has been resolved.

The analysis should connect compensation to payer economics and delivered hours. Labor cost per hour, supervision cost, non-billable time, cancellations, and productivity determine whether rate increases or wage changes improve or weaken contribution margin.

The company should also separate temporary wage pressure from structural labor economics. A buyer may accept a one-time retention initiative but will not add back compensation required to maintain the workforce. Cash-flow underwriting requires the recurring cost base to reflect the services actually delivered.

Compensation changes also affect client continuity and scheduling. A buyer that assumes immediate wage standardization, reduced guarantees, or new productivity expectations should test how those changes may affect retention and delivered hours. The transaction model should reflect the cost of preserving the clinical workforce during integration rather than assuming every policy change produces immediate margin improvement.

Center-based, in-home, school-based, and hybrid delivery economics

No delivery model is automatically superior. Buyers evaluate how each setting affects fixed cost, travel, staffing density, cancellations, supervision, capacity, payer rules, family preference, referral conversion, de novo growth, and integration.

Consolidated margins can hide significant setting-level variation. Buyers need contribution economics that allocate direct labor, supervision, travel, occupancy, cancellations, and administrative burden appropriately. A company should be able to explain why each delivery setting exists and how it supports the clinical and economic model.

Location-level economics and mature-center cohorts

Buyers do not assume every center has the same economics. They examine opening date, licensed or practical capacity, active and economic census, BCBA and RBT staffing, authorized and delivered hours, revenue, direct labor, supervision, occupancy, contribution margin, referral conversion, and break-even timing. Mature centers should be separated from recent de novos and centers undergoing remediation.

Cohort analysis shows whether new locations are repeating the historical model or requiring more time and capital. A company may report strong consolidated growth while mature centers decline and new centers absorb recruiting, occupancy, and management expense. Conversely, an immature center can be valuable when its staffing, referral, authorization, and delivery trends demonstrate a credible path to maturity.

Location-level data also supports integration decisions. The buyer may preserve high-performing local practices, consolidate underused space, change leadership, or slow expansion in markets where staffing and payer economics do not support the original plan.

When location-level performance is unavailable, buyers may apply conservative allocations or discount the expansion thesis. How Private Equity Firms Value Companies explains why a sponsor needs measurable operating drivers to connect current performance with future returns.

Center occupancy, scheduling density, and cancellation behavior

Center capacity should be measured against usable rooms, operating hours, clinical mix, supervision, staffing, and client schedules rather than gross square footage. A center can appear physically full while underutilized at certain hours or constrained by a shortage of BCBAs or compatible schedules.

Scheduling density affects labor and facility economics. Consistent blocks of care can improve RBT productivity and supervision. Fragmented schedules create gaps, overtime, and difficulty reassigning staff after cancellations. Buyers examine utilization by hour, day, clinician, client, and room to determine whether growth requires more space or better scheduling.

Cancellation analysis should separate family, clinician, school, payer, weather, and administrative causes. The company should track makeup hours and whether cancelled time becomes unproductive payroll. High cancellation rates can impair both revenue and workforce retention because technicians experience unstable schedules and income.

De novo center ramp and break-even economics

A proven de novo engine can support platform value, but buyers require evidence that site selection, leases, buildout, licensure, payer enrollment, referral development, assessment capacity, BCBA recruiting, RBT hiring, and working capital are repeatable. A list of target markets is not the same as an executable expansion model.

The ramp should identify capital and timing from lease signing through break-even. Buyers analyze pre-opening costs, occupancy, leadership, hiring, credentialing, referral conversion, authorization timing, initial client cohorts, delivered hours, and contribution margin. The model should account for delays rather than assuming every location follows the fastest historical opening.

Management bandwidth is part of the cost. Rapid openings can weaken existing centers by drawing clinical leaders, recruiters, and operators away from mature locations. A buyer will discount a de novo plan that depends on leadership capacity the company has not yet built.

De novo underwriting also affects capital structure. Capital Structure & Liquidity Advisory provides context for comparing the funding required for expansion with a sale, recapitalization, or other ownership alternative.

Geographic density and state concentration create different tradeoffs

Local density can improve recruiting, supervisor coverage, center management, route planning, referral relationships, payer knowledge, and brand awareness. A dense market can also create operating flexibility when clients or clinicians need to move among locations. Buyers often value that density more than a scattered multi-state footprint with little local scale.

State concentration creates exposure to one reimbursement and regulatory environment. Rates, authorizations, provider qualifications, documentation, licensure, Medicaid rules, audits, and enforcement can change. A company may have excellent local operations while remaining vulnerable to one state policy or managed-care relationship.

Diversification should be intentional. Entering additional states adds complexity and may not reduce risk if each market lacks density and management. The buyer needs a state-entry model covering payers, licensure, enrollment, clinical leadership, recruiting, compliance, and local referral development.

The comparison with I/DD Services M&A is useful because both subsectors can depend heavily on state reimbursement, workforce availability, and state-specific compliance. The operating evidence differs, but state concentration should be analyzed through both economics and regulatory transferability.

Multidisciplinary pediatric-services considerations

Some ABA platforms also provide speech, occupational, physical, feeding, diagnostic, or other pediatric services. The broader model can improve family access and referral continuity, but buyers should not assume every service line creates synergy. Each has different clinician supply, payer rules, coding, supervision, scheduling, and margin.

The buyer should evaluate whether services share clients, facilities, referrals, management, and clinical coordination or merely operate under one brand. Cross-referral claims should be supported by actual patient-flow data. The provider also needs clear professional boundaries, documentation, and compliance for each discipline.

The comparison with Healthcare Provider Services M&A is useful because multidisciplinary platforms can create broader value, but ABA economics should remain separately visible. Blended reporting can hide which service line drives growth or consumes management resources.

A buyer should also test whether multidisciplinary offerings improve lifetime value or simply add complexity. Specialty Physician Practice M&A provides adjacent context for evaluating multiple clinical disciplines without losing visibility into provider-level economics and governance.

Buyer-accepted EBITDA in ABA transactions

Reported EBITDA is the starting point, not the financed earnings base. Buyers normalize owner compensation, personal expenses, one-time costs, recruiting, turnover, overtime, agency labor, clinical leadership, revenue-cycle staffing, compliance, management, center ramp, and denied or unsupported revenue. Some adjustments increase EBITDA; others identify costs the buyer must add after closing.

Revenue adjustments can be more important than expense add-backs. Claims may be recorded before collection, and the buyer may challenge revenue associated with expired authorizations, missing documentation, credentialing gaps, excessive aging, or recoupment exposure. Quality of Earnings vs. Normalized EBITDA explains why financial and operating evidence must support the same earnings base.

The valuation analysis should connect accepted EBITDA to the specific operating drivers. Pharma Services Company Valuation may focus on backlog, clients, technical capabilities, quality systems, and capacity. ABA value depends more heavily on payer approvals, clinician capacity, delivered services, documentation, claims, collections, and compliance. The buyer cannot transfer a valuation method without transferring the underlying evidence.

The earnings base also needs to separate ownership return from clinical and executive compensation. Normalized EBITDA vs. Adjusted EBITDA explains why unsupported terminology is less important than a documented bridge that reflects the cost of operating after closing.

Quality of earnings and cash conversion

Quality-of-earnings diligence should reconcile the general ledger with claims, cash, clinical activity, and workforce data. Monthly revenue should make sense against delivered hours, payer rates, denials, and collections. Payroll should make sense against clinician rosters, hours, overtime, benefits, and vacancies. Center expenses should align with location-level reporting.

Cash conversion can be weaker than EBITDA because AR grows, payers delay, recruiting requires upfront spending, new centers consume working capital, and compliance or systems investment is deferred. The EBITDA to Free Cash Flow Bridge is central to lender and sponsor underwriting because debt service and investment returns are paid with cash rather than reported earnings.

A seller should prepare the bridge before market. Normalized EBITDA vs. Adjusted EBITDA, TTM EBITDA in M&A, and Run-Rate EBITDA in M&A provide useful mechanics for separating historical performance, recent changes, and forecast assumptions.

State Medicaid and regulatory exposure

ABA coverage and operating requirements vary by state and payer. Buyers review medical-necessity standards, prior authorization, provider qualifications, licensure, supervision, rendering-provider rules, documentation, telehealth, school and home delivery, credentialing, enrollment, rate methodology, and audit history. A multi-state provider needs a controlled process for identifying and implementing those differences.

State exposure should be quantified through revenue, clients, clinicians, locations, and contribution margin. The buyer also needs to know whether a particular state requires specialized systems or staffing that cannot be centralized. A policy or rate change can affect revenue and labor economics simultaneously.

Compliance analysis should distinguish identified issues from broad regulatory uncertainty. Organized policies, training, monitoring, claim sampling, corrective actions, and audit response can preserve value even when the environment is complex. Weak controls allow the buyer to assume the worst case.

The state-by-state analysis should connect with the financing case. Lenders and sponsors may apply more conservative assumptions when a large portion of EBITDA depends on one program, one managed-care organization, or one set of provider rules that the buyer has not previously operated under.

Documentation and billing controls

Buyers test whether each billed service is supported by the treatment plan, authorization, rendering provider, date, place, time, units, note, signature, and required clinical content. They may sample records by payer, center, clinician, and service type and compare the record with scheduling and claims data.

The purpose is not merely to find missing signatures. The buyer wants to know whether the company has a reliable control environment. Late notes, copied content, inconsistent time support, mismatched rendering providers, missing supervision, or treatment-plan gaps can indicate systemic risk even when individual claims appear collectible.

Management should understand how documentation exceptions are identified, corrected, trained, and monitored. A mature provider can show policies, audit results, exception trends, disciplinary or remediation processes, and whether changes reduced the recurrence rate. That evidence gives the buyer a basis for quantifying risk rather than applying a broad discount.

Documentation controls should be embedded in workflow rather than reconstructed for diligence. Buyers are more comfortable when the system prevents or flags incomplete records before billing and when management can show that exceptions are reviewed independently of the clinician who generated them.

Compliance diligence and claim sampling

Claim sampling connects clinical records with financial exposure. Buyers or advisers may select claims across payers, states, centers, clinicians, time periods, and codes to test whether the service was authorized, delivered by an eligible provider, documented, billed accurately, and paid appropriately.

A sample finding can have consequences beyond the specific claim. The buyer may extrapolate the issue, expand the sample, request repayment analysis, or require a special indemnity. The seller should understand whether the exception is isolated, historical, already remediated, or indicative of a wider process weakness.

Early preparation through How Buyers Identify Hidden Risk During Diligence and experienced support for protecting valuation through diligence can help management organize evidence and quantify remediation before isolated findings become broad assumptions.

What causes ABA buyers to pass or retrade

Buyers may reduce price or walk away when revenue cannot be reconciled to authorized and documented services, when a material portion of demand is unstaffed, when BCBA concentration is high, when RBT turnover undermines capacity, or when payer and state exposure exceed the buyer’s risk tolerance. Poor center economics, immature de novos, inconsistent reporting, compliance history, and unresolved credentialing can have the same effect.

Retrades often occur when the original indication depended on assumptions that later fail. The buyer may have assumed that all active clients were producing stable hours, that add-backs would be accepted, that centers were mature, or that claims support was clean. Diligence changes the economics when the evidence does not support those assumptions.

Preparation should identify the likely challenge and frame it with data. Experienced advisor support through diligence and closing can help separate legitimate risk from negotiation pressure, preserve comparable information across buyers, and maintain alternatives when one buyer changes its position.

When a buyer attempts to broaden one finding into a company-wide discount, the seller should respond with population data, root-cause analysis, remediation, and a reasoned estimate of exposure. The objective is not to dismiss the issue; it is to prevent an unsupported assumption from replacing transaction-specific evidence.

How buyers triangulate ABA value

ABA businesses are commonly valued through normalized EBITDA, private transaction evidence, comparable healthcare-services businesses, income methods, and buyer-specific return models. Market evidence is useful, but private transactions often omit rollover, earnouts, center maturity, payer mix, founder employment, and the accepted EBITDA adjustments that explain the headline multiple.

Strategic acquirers may support value through density, recruiting, payer, revenue-cycle, management, or facility synergies. Private equity buyers model leverage, organic growth, de novos, add-ons, integration, debt paydown, and exit value. How Buyers Build a Valuation Model explains how historical and forecast evidence becomes price.

The comparison with Pharma Services Valuation Multiples reinforces why subsector evidence matters. A multiple tied to backlog and technical capabilities cannot be applied mechanically to an ABA provider whose value depends on payers, workforce, authorizations, documentation, and collected service hours.

Multiples vs. DCF vs. Precedent Transactions provides a broader framework for triangulation. The ABA seller should expect market evidence to be adjusted for scale, state exposure, center maturity, workforce, payer mix, and the structure embedded in private transactions.

EBITDA multiples are an output, not the starting answer

A multiple summarizes judgments about earnings quality, growth, risk, scale, buyer fit, financing capacity, and future exit. Two ABA companies with the same reported EBITDA can receive different multiples because one has diversified payers, mature centers, a strong BCBA bench, stable RBT cohorts, low denial rates, and institutional reporting while the other depends on a few clinicians, one state, immature locations, and unsupported claims.

Buyers can adjust both the earnings base and multiple. They may reject a portion of the seller’s add-backs but pay a stronger multiple for the remaining transferable EBITDA. They may accept a higher earnings base but apply a lower multiple because the business requires significant post-close investment or carries concentrated payer and workforce risk.

What Actually Increases EBITDA Multiples in a Sale explains the broader factors, while the seller should focus on the ABA-specific evidence that makes the multiple defensible rather than citing an isolated range.

Why Businesses Sell for 10x EBITDA vs. 3x illustrates why transferability, scale, risk, and buyer fit create a wide range of outcomes. The principle applies to ABA, but the evidence must be drawn from payer, workforce, clinical, and center performance.

Leverage, lender underwriting, and financing certainty

Lenders evaluate buyer-accepted EBITDA, cash conversion, payer and state concentration, workforce stability, compliance, center maturity, management, working capital, and integration risk. A sponsor may model a transaction at one leverage level and later reduce the offer if lenders apply a lower earnings base or require more equity.

Financing certainty matters to sellers because a high indication supported by unresolved debt can be less valuable than a funded proposal with fewer conditions. The seller should understand which lenders have reviewed the transaction, whether commitments exist, and which diligence findings could change the capital structure.

Acquisition Financing Advisory, Debt Placement Advisory, and Sources and Uses in M&A provide context for how debt, sponsor equity, rollover, seller financing, fees, and other closing requirements fit together.

The lender may also require a downside case that assumes slower hiring, lower delivered hours, higher denials, or delayed center ramp. A transaction that remains financeable under those assumptions generally offers more closing certainty than one that depends on the seller’s most optimistic forecast.

Financing readiness should be assessed before the seller relies on an attractive sponsor indication. The buyer should be able to explain the assumed debt provider, leverage level, equity contribution, approval sequence, diligence conditions, and timing to commitment. If the financing case depends on aggressive delivered-hour growth, immediate staffing improvement, or a rapid reduction in denials, the seller should treat that dependency as part of closing risk rather than as a neutral model assumption.

The lender may also require reporting, covenant, and liquidity standards that affect the post-close operating plan. Those requirements can change how much cash remains available for recruiting, new centers, technology, compliance, and acquisitions. Sellers retaining rollover equity should understand whether the capital structure leaves enough flexibility to execute the growth case presented during negotiations.

Rollover equity, earnouts, escrows, and seller notes

Structure allocates uncertainty between buyer and seller. Rollover equity can preserve future upside but exposes the owner to leverage, dilution, governance, integration, and exit timing. Earnouts may bridge disagreement over growth, clinician retention, payer continuity, or center ramp. Escrows address indemnification or identified exposure. Seller notes can fill a financing gap but may be subordinated to senior debt.

The seller should evaluate the security, preferences, dilution, board and information rights, vesting, operating control, measurement definitions, dispute process, and payment priority. A nominally high enterprise value can include substantial contingent or retained value that is not equivalent to cash at closing.

Rollover and contingent structure should be evaluated together with employment and integration. The seller may remain responsible for clinical leadership or growth while lacking control over payer strategy, staffing budgets, acquisitions, or systems that affect the result. That allocation of control and risk should be explicit before exclusivity is granted.

Rollover Equity in M&A, Earnouts in M&A, and Seller Notes in M&A explain the mechanics. Experienced advice on seller proceeds and transaction structure helps owners compare the combined risk rather than negotiate each term in isolation.

Working capital, debt-like items, and seller proceeds

Enterprise value is the value of the operating business before the purchase-price bridge. Net debt, debt-like items, transaction expenses, working capital, escrow, rollover, earnouts, seller notes, and taxes determine the seller’s actual economics. ABA working capital can be sensitive to AR aging, payer timing, payroll cycles, credit balances, deferred revenue, and recoupment exposure.

The working-capital peg should reflect a normalized level required to operate after closing. Buyers may exclude aged or unsupported receivables and treat certain liabilities as debt-like. Debt-Like Items in M&A, Net Debt in M&A, and Purchase Price Adjustment in M&A explain why value can change after the multiple is agreed.

Owners should compare cash at close, deferred consideration, retained equity, obligations, and probability-weighted recovery. Enterprise Value vs. Purchase Price clarifies why headline enterprise value is not the final check.

Enterprise Value vs. Equity Value, Cash-Free, Debt-Free, and Completion Accounts vs. Locked Box provide additional context for how closing mechanics allocate balance-sheet and timing risk.

Illustrative ABA EBITDA and seller-proceeds bridge

The following simplified example shows how operational adjustments can change accepted EBITDA, enterprise value, and cash at close. It is not a valuation opinion or market range. The purpose is to demonstrate the interaction among authorizations, staffing, denials, supervision, structure, and purchase-price mechanics.

The example illustrates why sellers should prepare the operating evidence before buyers set the bridge. A company may still achieve a strong outcome, but the negotiation is more favorable when management can support authorizations, staffing costs, collections, center maturity, and required infrastructure with credible data.

Integration risk after closing

ABA integration can disrupt value through compensation changes, BCBA departures, RBT turnover, schedule changes, EMR migration, billing conversion, payer enrollment, authorization workflows, brand changes, parent communication, and clinical-governance changes. The buyer should sequence changes based on care continuity and reimbursement risk rather than pursuing immediate standardization.

Clinical and operating leaders should identify which systems must change, which can transition later, and which local practices preserve relationships or performance. The integration plan should assign owners to payer work, credentials, authorizations, data migration, payroll, schedules, documentation, communication, and retention.

Sellers with rollover or continued employment remain exposed to integration quality. The buyer’s historical record matters because retained value depends on whether prior acquisitions preserved clinicians, families, services, claims, and cash flow while creating better systems and scale.

The integration plan should be tested during diligence rather than treated as a post-closing project. The buyer should identify which systems will change, who owns the work, how authorization and enrollment continuity will be protected, and what metrics will determine whether the transition is succeeding.

Seller readiness and data-room preparation

An ABA data room should connect monthly financial statements, trial balances, payer and state revenue, client rosters, authorization files, scheduled and delivered hours, claims, collections, denials, AR, BCBA and RBT rosters, compensation, turnover, credentialing, center-level P&Ls, leases, referrals, waitlists, compliance, audits, overpayments, contracts, and management structure.

The goal is not document volume. It is reconciliation. Financial projections should connect to staffing and center capacity. Revenue should connect to delivered and documented services. Waitlist growth should connect to authorization and hiring plans. Center expansion should connect to site, payer, workforce, and working-capital assumptions.

Management should also prepare a clear exception narrative. Buyers do not expect every payer, center, clinician cohort, or claim file to be perfect, but they do expect the company to know where performance differs from policy or forecast. A credible explanation identifies the population affected, financial magnitude, root cause, remediation owner, timing, and evidence that the problem is improving. That level of control can preserve confidence even when diligence identifies a real issue.

How to Sell a Behavioral Health Company provides broader preparation context. How to Sell a Pharma Services Company provides a useful regulated-services comparison. Owners should consider engaging an M&A advisor for selling a business before direct buyer conversations create expectations or expose sensitive clinical, payer, or employee information.

Qualified buyer competition and offer comparison

Different buyers can value the same ABA business for different reasons. One may prioritize a new state, another mature centers, another commercial payer relationships, another school-based capabilities, and another a strong clinical leadership bench. Competition reveals which strengths create company-specific value.

The process should be controlled. Too few buyers leave the seller dependent on one underwriting view. Too many poorly qualified parties increase confidentiality risk and management burden. How a Competitive M&A Process Increases Value, M&A Auction Process Explained, and Why Multiple Buyers Increase Business Valuation explain how credible alternatives support price and terms.

Buyer qualification should occur before sensitive clinical and payer information is disclosed. The seller should understand the buyer’s capital, approvals, relevant operating experience, integration resources, confidentiality controls, and ability to evaluate reimbursement and compliance without creating unnecessary disruption. A credible buyer universe is defined by execution capability, not the number of names on an outreach list.

Timing and sequencing should also protect the operating business. Management attention is a scarce resource, and an ABA provider cannot allow buyer requests to interfere with authorization renewals, recruiting, supervision, family communication, or claims. A well-managed process organizes data and decision points so diligence advances without weakening the performance the buyer is evaluating.

Offers should be compared across accepted EBITDA, enterprise value, cash at close, rollover, earnouts, escrows, working capital, financing, approvals, employment, integration, and closing conditions. Experienced offer comparison and negotiation support helps preserve leverage until the strongest risk-adjusted proposal is selected.

Why advisor discipline affects realized value

Advisor value in ABA transactions is not simply identifying private equity firms. It includes preparing the referral-to-cash evidence, distinguishing platform and add-on positioning, qualifying buyers, staging sensitive clinical and payer information, coordinating financial and compliance workstreams, comparing financing and approvals, and preserving competition before exclusivity.

Owners evaluating representation should review How Buyers Evaluate M&A Advisors, Evaluate a Sell-Side M&A Advisor, and M&A Advisor vs. Business Broker vs. Investment Bank. The adviser should understand how buyers connect clinical operations, reimbursement, workforce, and claims to valuation and structure.

What Does a Sell-Side M&A Advisor Do? explains the broader representation role. In ABA, that role should include coordinating complex operating and compliance evidence without allowing the process to become a substitute for qualified legal, accounting, clinical, reimbursement, or regulatory advice.

Process discipline also affects credibility. Comparable information, controlled access, clear deadlines, responsive diligence, and accurate framing make it harder for one buyer to redefine the company after exclusivity. Sell-Side M&A Process explains the transaction stages without confusing those stages with the separate role of sell-side representation.

Seller takeaway

Frequently asked questions

Related Auxo resources

ABA transaction outcomes depend on more than a valuation multiple. Owners should connect operating evidence, diligence readiness, working capital, offer structure, advisor fit, and the mechanics that determine actual seller proceeds.

M&A, capital, and valuation resources

• Mergers & Acquisitions Advisory Services — Auxo’s broader advisory hub for founder-led and middle-market companies evaluating sales, acquisitions, recapitalizations, and strategic alternatives.
• Sell-Side M&A Advisory Services — Relevant for owners who need preparation, buyer outreach, negotiation, diligence, structure, and closing support.
• Capital Advisory Services — Helps owners compare a full sale with recapitalization, minority investment, debt, and growth-capital alternatives.
• Business Valuation Calculator — A first-pass tool for testing how EBITDA, multiple assumptions, debt, and working capital affect value.

Diligence and transaction mechanics

• Quality of Earnings: What Buyers Flag — Reviews the revenue, expense, add-back, and cash-conversion issues that commonly change accepted EBITDA.
• Why Deals Lose Value During Due Diligence — Explains how weak support, inconsistent data, and late discoveries can erode price and certainty.
• Working Capital: Avoid Price Chips — Shows how a poorly supported peg or AR analysis can transfer value after the multiple is agreed.
• Enterprise Value to Seller Proceeds — Connects headline value with debt, working capital, escrow, rollover, contingent value, fees, and actual proceeds.

Offer evaluation and advisor selection

• Why Letters of Intent Are Not Final Value — Reviews the assumptions, diligence, financing, and terms that can change after an LOI is signed.
• How Founders Should Compare Two M&A Offers — Provides a framework for comparing cash, rollover, contingent value, retained risk, and certainty.
• Why the Highest Price Isn’t Always the Best Buyer — Explains why financing, structure, fit, integration, and probability of close matter alongside price.
• Choosing the Right M&A Advisor: 2026 Guide — Reviews senior involvement, buyer access, sector understanding, process discipline, and alignment.

Used together, these resources help ABA and autism-services owners move from broad buyer interest to the questions that determine outcome: which earnings can be defended, how diligence will test clinical and claims support, how offers allocate reimbursement and workforce risk, and which buyer can preserve care continuity while executing the transaction.

Media & press inquiries

Auxo Capital Advisors welcomes inquiries from journalists, editors, podcast producers, and event organizers covering middle-market M&A, ABA and autism services, behavioral health consolidation, private equity, payer and workforce underwriting, and transaction strategy.

For media requests related to this article, please email info@auxocapitaladvisors.com.

About the author

George Barsom is Founder & Managing Director of Auxo Capital Advisors. He advises founder-led and middle-market businesses on valuation, sell-side preparation, transaction positioning, and M&A execution.

His work focuses on translating operating performance into buyer-relevant underwriting narratives so owners can approach a sale, recapitalization, or capital process with clearer expectations around value, structure, and diligence risk. Auxo’s core practice areas include Mergers & Acquisitions Advisory Services, Capital Advisory Services, and Valuation Services.

Disclosure

This article is provided for general informational purposes only and reflects a transaction advisory perspective on how buyers may evaluate ABA therapy, autism services, pediatric therapy, behavioral health, and related healthcare services companies in middle-market sale, recapitalization, capital-raising, or acquisition processes. It is not legal, tax, accounting, investment, reimbursement, regulatory, clinical, privacy, valuation, or other professional advice, and it should not be relied on as a substitute for transaction-specific guidance. Ownership, licensure, credentialing, enrollment, documentation, billing, privacy, clinical-governance, and other requirements vary by company, service model, payer, state, and transaction structure and require advice from qualified professionals.

Any examples, ranges, scenarios, formulas, buyer profiles, or illustrative valuation bridges are simplified for explanatory purposes. Actual outcomes depend on buyer-specific underwriting, diligence findings, payer and referral relationships, authorizations, census, clinician capacity, compliance, financing, legal and tax structuring, working capital, net debt, facility and lease obligations, market conditions, employment terms, integration plans, and company-specific facts. No valuation outcome, buyer interest level, multiple, financing result, or deal structure is implied or guaranteed.

Third-party references to, citations of, summaries of, or links to this article do not constitute Auxo Capital Advisors’ review, approval, endorsement, affiliation, or adoption of any third party’s statements, services, conclusions, data, valuation ranges, transaction guidance, clinical claims, or regulatory representations. Auxo Capital Advisors is not responsible for the accuracy, completeness, context, or use of this article by any third party.

This article and its original text, analysis, frameworks, tables, graphics, and organization are protected content of Auxo Capital Advisors. Limited quotation with clear and accurate attribution is permitted for legitimate commentary or reference. Reproduction, substantial paraphrasing, republication, commercial reuse, scraping, dataset creation, model training, or other artificial-intelligence training or retrieval use is prohibited without prior written permission.